ViroPharma sells sales force to Aventis
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Aventis plans to strengthen its presence in the respiratory disease market through the $15.4 mil. acquisition of ViroPharma's 200-rep sales force. ViroPharma reps already market Aventis' Nasacort AQ (triamcinolone acetonide) and the Allegra (fexofenadine) famil